2022-501992-15-00招募中2 期
A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercaptopurine (6-MP) in combination with VPA in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) considered unfit for standard chemotherapy
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 6
- 主要终点
- Safety and tolerability assessed by monitoring the incidence, frequency and severity of AEs, including evaluation of the following: i. DLTs ii. Physical examinations iii. Clinical laboratory blood and urine samples
研究概览
简要总结
- To determine the safety and tolerability of the treatment combination of hydroxyurea and valproic acid administered at established clinical doses
- To establish the preliminary efficacy (clinical benefit as defined by this protocol) of the treatment combination of hydroxyurea and valproic acid administered at established clinical doses
- To establish the preliminary efficacy (clinical benefit as defined by this protocol) of the treatment combination of 6-mercaptopurine and valproic acid administered at established clinical doses
- To evaluate changes in patients performance status for baseline and during the study period
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Female or male, age 18 years or older
- •Written informed consent
- •Patients NOT eligible for standard therapy (ELN 2022 ), defined as HCT-CI ≥ 3
- •Patients NOT eligible for standard therapy for other reasons, including patient’s choice of therapy
- •Patients with a diagnosis of AML according to ELN 2022 classification, or relapsed / refractory AML, or sAML (MDS-related/ therapy- induced), or high-risk MDS, or acute promyelocytic leukemia not eligible for standard therapy and/or specific therapy
- •Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values: (a) Serum creatinine ≤1.5 x ULN; (b) Estimated creatinine clearance ≥40 mL/min (Cockcroft-Gault equation); (c) Hepatic function; i. Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); ii. Aspartate aminotransferase (AST)
- •≤5 × ULN for patients with liver metastases iii. Alanine aminotransferase (ALT)
- •≤5 × ULN for patients with liver metastases iv. Alkaline phosphatase (ALP)
- •European Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- •Breastfeeding women
- •Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to taking their first dose of study medication. Male patients and female patients of reproductive potential must agree to practice highly effective methods of contraception (such as hormonal implants, combined oral contraceptives, injectable contraceptives, intrauterine device with hormone spirals, total sexual abstinence, vasectomy) throughout the study and for >3 months after the last dose of study medication. Female patients are considered NOT of childbearing potential if they have a history of surgical sterility or evidence of post-menopausal status defined as any of the following: (a) Natural menopause with last menses >1 year ago (b) Radiation induced oophorectomy with last menses >1 year ago (c) Chemotherapy induced menopause with last menses >1 year ago
排除标准
- •Patients on treatment for AML (any anti-leukemic therapy including investigational agents) or treated less than 2 weeks before inclusion
- •Known hypersensitivity to study medications or its excipients
- •Any psychological, familial, sociological, and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- •Concurrent history of active malignancy in the past six months prior to diagnosis except for: (a) basal and squamous cell carcinoma of the skin (b) in situ carcinoma of the cervix
- •Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease et cetera) at the investigators discretion.
- •Cardiac dysfunction as defined by: (a) myocardial infarction within the last 3 months of study entry, or (b) medical history recorded reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or (c) congestive heart failure NYHA class IV or (d) unstable angina, or (e) unstable cardiac arrhythmias
- •SARS-CoV-2 infection < 7 days or Covid-19-vaccine < 7 days from study onset
- •Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance
- •Patients with any serious concomitant medical condition that could, in the opinion of the investigator, compromise participation in the study.
- •Patients with senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
- •Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
结局指标
主要结局
Safety and tolerability assessed by monitoring the incidence, frequency and severity of AEs, including evaluation of the following: i. DLTs ii. Physical examinations iii. Clinical laboratory blood and urine samples
Safety and tolerability assessed by monitoring the incidence, frequency and severity of AEs, including evaluation of the following: i. DLTs ii. Physical examinations iii. Clinical laboratory blood and urine samples
Determine clinical benefit (as defined by this protocol) in patients receiving hydroxyurea in combination with valproic acid
Determine clinical benefit (as defined by this protocol) in patients receiving hydroxyurea in combination with valproic acid
Determine clinical benefit* in patients receiving 6-mercaptopurine in combination with valproic acid
Determine clinical benefit* in patients receiving 6-mercaptopurine in combination with valproic acid
Baseline and longitudinal ECOG status of the patient (Eastern Cooperative Oncology Group)
Baseline and longitudinal ECOG status of the patient (Eastern Cooperative Oncology Group)
次要结局
- (a) The percentage of patients with clinical benefit after 3 and 6 cycles in each arm ( A1, A2, B1, B2) (b) Overall response rate (ORR; defined as the percentage of patients with a response of CR, CRh, CRi, MLFS, PR or no response as assessed by ELN response criteria 2022) (c) Duration of clinical benefit (d) Time to progression (e) Overall Survival (OS)
- Usage of health-related quality of life questionnaires: i. EQ -5D-5L ii. SF-36, QLQ-C30 iii. NCI- PRO-CTCAE (b) Lower number of hospital admissions and blood-/platelet transfusions during and after study investigation compared to baseline.
研究者
Bjørn Tore Gjertsen
Scientific
Helse Bergen HF
研究点 (6)
Loading locations...
相似试验
招募中
3 期
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliaNCT07285460Sanofi85
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
招募中
1 期
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid TumorNCT07275242Suzhou Suncadia Biopharmaceuticals Co., Ltd.107
进行中（未招募）
1 期
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors2024-513716-95-00Nec Oncoimmunity AS6